Point-of-care monitoring for optimal antiplatelet therapy in acute clinical settings

Point of Care

Volumn 6, Issue 3, 2007, Pages 208-212

  Guyer, Kirk E ^a   Carville, David G M ^a,c   Ridgway, Helen ^b,c   Rullman, Richard L ^b,c  

^a INDIANA UNIVERSITY SOUTH BEND   (United States)

^b Helena Laboratories   (United States)

^c Helena POC ^*

Author keywords

Acute clinical settings; Monitoring antiplatelet therapy; Point of care

Indexed keywords

EID: 34548427817     PISSN: 1533029X     EISSN: 15330303     Source Type: Journal    
DOI: 10.1097/poc.0b013e31812e94f0     Document Type: Conference Paper

References (28)

1. Born GVR, Cross MJ. The aggregation of blood platelets. J Physiol. 1963;168:178-195.
2. Born GVR, Hardisty RM. Platelets. In: Biggs R, ed. Human Blood Coagulation, Haemostasis and Thrombosis. 2nd ed. London: Blackwell Scientific Publications; 1976:168-201.
3. Storey RF, Wilcox RG, Hepinstall S. Differential effects of glycoprotein GPIIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency: implications for assay methodology and comparison of different antagonists. Circulation. 1998;198:1616-1621.
4. Carville DGM, Guyer KE, Schlesker P, et al. Whole blood platelet function assay on the ICHOR point-of-care hematology analyzer. J Extra Corpor Technol. 1998;30(4):171-177.
5. Shaffer KE, Pearman DT, Galen RS, et al. A rapid platelet function assay used to regulate platelet transfusion prophylaxis following cardiopulmonary bypass surgery. J Extra Corpor Technol. 2004;36(2):145-148.
6. Lau WC, Walker CT, Ogilby JD, et al. Evaluation of a near patient platelet function assay - performance and clinical utility. Ann Card Anaesth. 2002;5(5):33-42.
7. Carville DGM, Guyer E. Hemostasis testing: past, present, and future. IVDT. 2000;6(5):49-56.
8. Kelly RV, Steinhubl S. Changing roles of anticoagulant and antiplatelet treatment during percutaneous coronary intervention. Heart. 2005;91:iii16-iii19.
9. Steinhubl SR, Berger PB, Mann JT, et al, for the CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-2420.
10. Podczasy JJ, Lee J, Vucenik I. Evaluation of whole-blood lumi-aggregation. Clin Appl Thromb Hemost. 1997;3(3):190-195.
11. Mammen EF, Comp PC, Gosselin R, et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost. 1998;24(2):195-202.
12. Smith JW, Steinhubl SR, Lincoff AM. Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation. 1999;99:620-625.
13. TEG. Available at: http://www.anes.saga-med.ac.jp/ispub/journals/IJA/ Vol1N3/teg.htm. Accessed July 6, 2007.
14. ASAwrks. Available at: http://stat-technologies.com/index.php?module= pagemaster PAGE_id=26&MMN_position=50:50. Accessed July 6, 2007.
15. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
16. Antiplatelet and antithrombotic prescribing guide. Thompson Medical Economics: Montvale, NJ; 2003.
17. Bates ER, Mukherjee D, Lau WC. Drug-drug interactions involving anti-platelet agents. Eur Heart J. 2003;24:1707-1709.
18. Jarvis B, Simpson K. Clopidogrel: a review of its use in the prevention of atherothrombosis. Drugs. 2000;60:247-277.
19. Breddin HK. Can platelet aggregometry be standardized? Platelets. 2005;16(3-4):151-158.
20. Eikelboom J, Hirsch J, Wietz J, et al. Aspirin resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002;105:1650-1655.
21. Eidelman RS, Herbert PR, Weisman S, et al. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med. 2003;163(17):2006-2010.
22. Harrington RA, Hodgson PK, Larsen RL. Antiplatelet therapy. Circulation. 2003;108:e45-e47.
23. Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol. 2005;46(9):1705-1709.
24. Cattaneo M. Aspirin and clopidogrel - efficacy, safety and the issue of drug resistance. Arterioscler Thromb Vasc Biol. 2004;24:1980-1987.
25. Gum P, Kottke-Marchant K, Poggio E, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001;88:230-235.
26. Muller I, Bestas F, Schultz C, et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost. 2003;89:783-787.
27. Guyer KE, Carville DGM, Lau WC. Platelet protection using the glycoprotein IIb/IIIa inhibitor tirofiban in a patient with heparin induced thrombocytopenia undergoing aortic valve replacement requiring cardiopulmonary bypass. Point of Care. 2003;2(2):119-124.
28. Steinhubl SR, Talley JD, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-assessing Ultegra) multicenter study. Circulation. 2001;103:2572.